Research
Print page Print page
Switch language
The Capital Region of Denmark - a part of Copenhagen University Hospital
Published

Involved node radiation therapy in the combined modality treatment for early-stage Hodgkin lymphoma: Analysis of relapse location and long-term outcome

Research output: Contribution to journalJournal articleResearchpeer-review

  1. Diffusion MRI outlined viable tumour volume beats GTV in intra-treatment stratification of outcome

    Research output: Contribution to journalJournal articleResearchpeer-review

  2. Diabetes increases the risk of serious adverse events after re-irradiation of the spine

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Influence of volumetric modulated arc therapy and FET-PET scanning on treatment outcomes for glioblastoma patients

    Research output: Contribution to journalJournal articleResearchpeer-review

  1. ILROG Lymphoma Mini-Atlas Part II, Hodgkin Lymphoma

    Research output: Contribution to journalEditorialResearchpeer-review

  2. Outcome in patients with isolated regional recurrence after primary radiotherapy for head and neck cancer

    Research output: Contribution to journalJournal articleResearchpeer-review

  3. Biological optimization for mediastinal lymphoma radiotherapy - a preliminary study

    Research output: Contribution to journalJournal articleResearchpeer-review

View graph of relations

BACKGROUND AND PURPOSE: Involved node radiation therapy (INRT) in the combined modality treatment for early-stage Hodgkin lymphoma (ESHL) has reduced the irradiated volume dramatically. Limiting the irradiated volume further based on initial disease bulk, 18F-fluoro-deoxy-glucose (FDG)-avidity, or residual computed tomography (CT) abnormality after chemotherapy seems attractive. In a cohort of patients treated with INRT a meticulous pattern-of-relapse analysis was performed to examine these options.

MATERIAL AND METHODS: Patients treated for ESHL in our institution from 2005 to 2014 who achieved complete remission with chemotherapy were included. Patient characteristics, treatment details and clinical outcome were registered. For relapsed patients, rigid co-registration of the positron emission tomography/computed tomography-scans from the time of diagnosis and at relapse was done to visually assess the relapse location relative to initial involvement and, if irradiated, the irradiated volume. Size and maximum Standardized Uptake Value of the initial node(s) with later relapse, and residual CT abnormalities after chemotherapy in those locations were measured.

RESULTS: We included 182 patients. Twelve (6.6%) patients relapsed, five in previously involved nodes (two irradiated, three not irradiated). Relapses did not occur preferentially in initially bulky disease, in lymph node(s) with the highest FDG-uptake, or in residual CT abnormalities after chemotherapy.

CONCLUSIONS: Modern treatment with brief chemotherapy and limited radiotherapy provides excellent long-term disease control in ESHL. Neither bulk, high FDG-uptake, nor residual CT abnormality after chemotherapy could predict initially involved lymph nodes with a high risk of relapse.

Original languageEnglish
JournalRadiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology
Volume150
Pages (from-to)236-244
Number of pages9
ISSN0167-8140
DOIs
Publication statusPublished - Sep 2020

    Research areas

  • Hodgkin lymphoma, Image co-registration, Involved node radiation therapy, Relapse location

ID: 60922332